Nuvation Bio Announces EAP in the US for Taletrectinib in Advanced ROS1-positive NSCLC February 5, 2025
Primary Endpoint Met in Ph 2b Trial of Zipalertinib in Patients with NSCLC with EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy February 5, 2025
Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Ph 2b Trial of IGV-001 in Newly Diagnosed GBM February 5, 2025
BRAFTOVI Combination Regimen Significantly Improved PFS and OS in Ph 3 BREAKWATER Trial February 5, 2025
Enhertu approved in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies February 5, 2025
